October 2018 - Evolution Biotechnologies
archive,date,ajax_fade,page_not_loaded,,qode-title-hidden,qode-theme-ver-16.4,qode-theme-bridge,wpb-js-composer js-comp-ver-5.4.7,vc_responsive

Bedford, UK, 3 October 2018 ­Evolution Biotechnologies (www.evolutionbiotech.com), the UK and US-based company extending the use of biological control into medically important areas, today announced its intention to present at the LSX World Congress USA, to be held in Boston from 10 to 11 October, 2018. CEO, Dr. David Harper, will present a summary of the company’s activities, as well as an update on its current and planned development streams. About Evolution Biotechnologies Evolution Biotechnologies (UK company 09473027) has been established to extend the application of biological control from its agricultural roots into areas of biomedical importance. The company’s initial targets have both...